Amgen Reports Phase 2 CodeBreaK 100 Results for Lumakras in KRAS G12C NSCLC

Amgen today announced results from the Phase 2 CodeBreaK 100 trial evaluating Lumakras (sotorasib) in patients with previously treated KRAS G12C-mutated non-small cell lung cancer. The trial demonstrated an overall response rate of 37.1%, with a median duration of response of 11.1 months. These results led to FDA accelerated approval of Lumakras for KRAS G12C-mutated NSCLC.